SCYNEXIS, Inc. (SCYX)

Over the past six months, SCYNEXIS was granted a 180-day extension by Nasdaq to regain compliance with the minimum bid price requirement on December 22, 2025. The company completed the transfer of its BREXAFEMME New Drug Application to GSK on November 19, 2025. On November 17, 2025, SCYNEXIS announced federal funding for a collaboration to develop new therapeutics for resistant fungal infections. SCYNEXIS reported its Third Quarter 2025 Financial Results and provided a corporate update on November 5, 2025. A disagreement with GSK regarding the restart of the Phase 3 MARIO Study was resolved on October 15, 2025. The company announced positive results from a Phase 1 study of its second-generation fungerp (SCY-247) on September 30, 2025. On September 4, 2025, SCYNEXIS announced multiple presentations highlighting data from SCY-247 at the 12th Congress on Trends in Medical Mycology (TIMM-12). SCYNEXIS participated in the H.C. Wainwright 27th Annual Global Conference on August 25, 2025. The company reported its Second Quarter 2025 Financial Results and provided a corporate update on August 13, 2025. The share price of SCYX experienced a decline of 45.33% from January 10, 2025 to January 9, 2026, and over the past six months, the stock has seen a change of -12.59%.

Based on the available information, there is no explicit indication of demand seasonality for SCYNEXIS, Inc.'s products and services, as the company focuses on therapies for fungal infections, which typically do not exhibit seasonal demand patterns.

SCYNEXIS, Inc. is a biotechnology company focused on discovering, developing, and commercializing innovative medicines for difficult-to-treat and drug-resistant infections, operating in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry. The company's major product is BREXAFEMME, approved for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC. Its lead product candidate, ibrexafungerp, is in clinical development for various serious fungal infections. The company is also developing SCY-247, a second-generation fungerp, to treat systemic fungal diseases.

SCYNEXIS, Inc. is headquartered in Jersey City, New Jersey, United States. While it directly markets BREXAFEMME in the United States, the company has research collaborations and licensing agreements with international partners for the global development and commercialization of ibrexafungerp, including GSK, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC.

SCYNEXIS's brand reputation has been influenced by analyst sentiment, positive study results, federal funding for collaborations, and partnerships with GSK. Analyst sentiment is generally positive, with a consensus rating of 84.44 out of 100. However, MarketBeat reports a "Hold" consensus rating. The Nasdaq's grant of a 180-day extension to regain compliance with the minimum bid price requirement and a substantial decline in stock price may impact investor confidence.

SCYNEXIS, Inc. has a significant level of institutional ownership, with 55 institutional owners holding 28.03% of the company's shares. Major institutional owners include Avidity Partners Management LP, Kingdon Capital Management, L.L.C., Vanguard Group Inc, Federated Hermes, Inc., Geode Capital Management, Llc, Acadian Asset Management Llc, Blackrock, Inc., AMH Equity Ltd, Yakira Capital Management, Inc., and Renaissance Technologies Llc. Hedge funds hold 16.1% of the shares, while the general public owns 66.9%, and individual insiders hold 2.17%.